Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kite announces manufacturing process change to improve turnaround time for Yescarta CAR-T therapy. The improvement pales in comparison to what Gracell has demonstrated.
https://www.gilead.com/news-and-press/press-room/press-releases/2024/1/kite-receives-us-fda-approval-of-manufacturing-process-change-resulting-in-reduced-median-turnaround-time-for-yescarta-car-tcell-therapy
Good luck to CtyoDyn on the resubmission of their revised HIV clinical trial protocol to the FDA. They also announced that their partnership with Montefiore and Albert Einstein College plans to move forward with a pre-clinical trial designed to study leronlimab in glioblastoma, which is also an indication that Humanigen has studied for treatment. It's good to see researchers focus on immunomodulators as treatment therapeutics for these indications.
https://www.globenewswire.com/news-release/2024/02/01/2821970/19782/en/CytoDyn-Announces-Submission-of-Clinical-Protocol-to-FDA-and-Initiation-of-Pre-Clinical-Study-in-Glioblastoma.html
Here's something interesting, eb.
Humanigen published top line data (TLD) just after one year of initiating the LIVE-AIR trial.
https://ir.humanigen.com/English/news/news-details/2021/Humanigen-Reports-Positive-Phase-3Topline-Results-Demonstrating-That-Lenzilumab-Improves-Survival-Without-Need-for-Mechanical-Ventilation-in-Hospitalized-Patients-With-COVID-19/default.aspx
That was a wake up call that Pfizer and the PfDA faced the potential loss of billions in revenue, and in commercial support of FDA operations.
Prior to that, we had restructured from Kalobios to Humanigen, and also executed the recall of our loaned shares in November of 2015. But it wasn't until Humanigen proved their bona fides with the LIVE-AIR TLD that the SEC came to the FDA's defense.
Within months of Humanigen's TLD, the SEC filed charges against Murchinson (and indirectly against Dale, in my opinion) in August of 2021.
https://www.sec.gov/news/press-release/2021-156
"According to the SEC's order, from June 2016 through October 2017, the respondents provided erroneous order-marking information on hundreds of sale orders of their hedge fund client to the hedge fund's brokers, causing those brokers to mismark the hedge funds' sales as "long." The order finds that in providing the inaccurate information, the respondents also caused the hedge fund’s brokers to fail to borrow or locate shares prior to executing the sales. The order further finds that Murchinson and Bistricer caused the hedge fund to engage in dealer activity without registering with the SEC or being exempt from registration."
And the Admin Proceeding was filed as an SEC enforcement action, as usual.
https://www.sec.gov/files/litigation/admin/2021/34-92684.pdf
The charges were filed 5 years after the fact, and amount to bullshit. The SEC didn't dare to file an enforcement action as they should have. Instead, they filed a civil suit, which I only found out about when Agrippa posted an AI-generated notification in this regard.
"AgrippaAntinous
Jan 03, 2024 1:29 PM
$HGENQ interesting conversation with AI:
sec vs dale chappell et al and black horse. what is accusation
According to the web search results, the accusation is that Dale Chappell and his entities, Black Horse Capital LP, Black Horse Capital Master Fund Ltd, and Cheval Holdings Ltd, engaged in a fraudulent scheme to misappropriate millions of dollars from investors and manipulate the market for certain publicly traded securities12. The SEC filed a complaint against them in the U.S. District Court for the Eastern District of Pennsylvania on August 11, 2023, alleging violations of the antifraud provisions of the federal securities laws12. The case is currently pending in the U.S. Court of Appeals for the Third Circuit, where the defendants have appealed the district court’s order granting a preliminary injunction and freezing their assets13. The case is scheduled for oral argument on January 16, 2024."
https://stocktwits.com/AgrippaAntinous/message/556601076
I looked up the AI-generated reference.
"August 11, 2023 Opinion or Order Filing 1 APPLICATION AND ORDER FOR EXEMPTION FROM THE ELECTRONIC PUBLIC ACCESS FEES BY LI HUANG; THIS EXEMPTION IS VALID UNTIL 12/31/2023; THIS EXEMPTION MAY BE REVOKED AT THE DISCRETION OF THE COURT AT ANY TIME; A COPY OF THIS ORDER SHALL BE SENT TO PACER SERVICE CENTER. SIGNED BY CHIEF JUDGE JUAN R. SANCHEZ ON 8/11/23. 8/11/223 ENTERED & E-MAILED. COPY SENT TO PACER SERVICE CENTER. (fdc)"
https://dockets.justia.com/docket/pennsylvania/paedce/2:2023mc00115/612553
I noted that the petitioner, Li Huang (also spelled Liu Huang) apparently works for the NIH.
"Li Huang
Application and Data Manager at NIH/NICHD
Rockville, Maryland, United States Contact Info
74 followers 72 connections
https://www.linkedin.com/in/li-huang-ab95437
Dale's Appeal to the Third Circuit, which is largely sealed, was calendared for Jan 16th, and I see no change to that.
https://dockets.justia.com/docket/circuit-courts/ca3/23-2776
I think this Appeal is critical for us, since our assets were frozen.
I also think Dale prevailed in his Appeal, and that is why we see the disputes in the bankruptcy case have been worked out.
"TwongStocks
Jan 25, 2024 2:20 PM
$HGENQ Docket 64, 2nd revision to bid procedures.
document.epiq11.com/documen...
Seems the parties have worked out their issues. Per para 5, the US Trustee and UCC do not object to this revision. Taran does not consent or object. So as long as there are no more objections, the Court will likely finalize the bid procedures order."
https://stocktwits.com/TwongStocks/message/559238962
I remain highly confident that Humanigen will be able to initiate a new recall of their loaned shares. Management has not bowed to the superior firepower of the SEC, NIH, NIAID, and the FDA, and I look forward to our future.
"Well done!!" Thanks, shajandr.
The increased need to avoid IMV in rural intermediate care units.
"Wednesday, January 31, 2024
NIH study shows higher mortality rates for patients on respiratory support in rural intermediate care units"
https://www.nih.gov/news-events/news-releases/nih-study-shows-higher-mortality-rates-patients-respiratory-support-rural-intermediate-care-units
"Survival without Ventilation (SWOV)" was the primary endpoint of the company's LIVE-AIR trial, and the just-released NIH study highlights the importance of getting lenz approved, especially for rural intermediate care units.
As covid hit, my best buys were in the 90 cent range.
04/24/2020 Buy
Trade Details HGEN
$0.91
04/24/2020 Buy
Trade Details HGEN
$0.999
My best sells were as follows.
03/29/2021 Sell
Trade Details HGEN
$27.78
03/29/2021 Sell
Trade Details HGEN
$29.07
My exits were on the day that Humanigen announced positive top line data of the LIVE-AIR trial, just one year after covid hit the US.
https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Reports-Positive-Phase-3-Topline-Results-Demonstrating-That-Lenzilumab-Improves-Survival-Without-Need-for-Mechanical-Ventila-O9C2T.pdf
Even more significant was the earlier announcement that the company was recalling their loaned shares.
"The penny stock company said just days before Shkreli's purchase that "it would wind down operations and liquidate assets, adding that any expectation of strategic alternatives were "highly unlikely." The company said it would discontinue two development programs, in Phase 1 and Phase 2 stage, adding it would not be able to file its Form 10-Q for the third quarter."
Shkreli has since been named the chief executive officer of KaloBios. A stock that at one point traded below $0.50 per share this year hit a high of $45.82 last week. On Thursday afternoon, Shkreli some other interesting news.
"I spoke with my counsel & advisers and decided to stop lending my $KBIO shares out until I better understand the advantages of doing so," Shkreli said. "I apologize for any inconvenience this may create in lending markets and I will probably resume lending at some point. Happy Thanksgiving!"
https://finance.yahoo.com/news/why-martin-shkreli-no-longer-155239570.html
So I share your excitement that we could be seeing, "Exactly the same..." things that we have seen before.
I kinda like my PA. She finally made it into the exam room 30 minutes late. She took in my skrungy appearance and listened as I told her how I felt that I had been hit by a truck. She knows that I don't like taking medicine or seeing doctors. She did offer to recommend some OTC drugs, but she could have just as easily been offering to get me a cherry sucker. But what else should she do? She had my lab results which she described as "perfect." And she set my next appointment in July.
I think she was just bemused by my not feeling well, because I just don't seem to get sick. I'm starting to feel better this morning.
Will today be the day that I need lenz? It was last Monday that I had a lab appointment at my doctor's office, and I have felt that I was hit by a truck for a week now. I'm scheduled to see the doctor for a follow-up today.
There are no FDA approved treatments for covid in the US.
I could get Paxlovid, but I have no confidence in that Pfizer product that researchers are finding 10X higher reinfections than the company reports. I'm not going to let the doctor prescribe it for me.
"The U.S. Food and Drug Administration (FDA) hasn’t approved any drugs that can treat COVID-19..."
https://www.yahoo.com/lifestyle/covid-19-antiviral-drugs-promise-200554966.html
Talk about a reality check. I'm really hoping that if lenz is used as a Novavax vaccine adjuvant, then the medical community will catch on to using lenz once covid is diagnosed, even before CRP levels are elevated to the point where patients have to be hospitalized.
"When a young, healthy person in the U.S. catches COVID-19, there’s not much they can do except stay home and rest." That wouldn't have worked in 2020, and I don't think that guidance will work in future variants. especially when mutations can be manipulated.
A second Statement of acquisition of beneficial ownership has been filed for Novavax in the last two days, this one filed by BlackRock.
https://www.sec.gov/Archives/edgar/data/1000694/000108636424004696/us6700024010_012624.txt
Thanks for sharing your exit strategy, eb. Here are my open orders.
GBLX
G B SCIENCES INC
Open
Sell 4,700 Limit $2.00 GTC
Exp 07/22/2024
HGENQ
HUMANIGEN INC
Open
Sell 6,500 Limit $200.01 GTC
Exp 07/02/2024
HGENQ
HUMANIGEN INC
Open
Sell 3,500 Limit $200.00 GTC
Exp 07/02/2024
Of interest is that Li Huang is described as Application and Data Manager at NIH/NICHD Rockville, Maryland, United States. He is also the Petitioner in the District Court Case.
https://www.linkedin.com/in/li-huang-ab95437
https://dockets.justia.com/docket/pennsylvania/paedce/2:2023mc00115/612553
And just to keep apparently related case info together, here again is the link to the Appeals Court.
https://dockets.justia.com/docket/circuit-courts/ca3/23-2776
I'm totally lost by not seeing SEC enforcement actions in terms of either an Admin Proceeding or a Litigation Release. I hope you can get a positive fill on your highest priced sell orders. I feel somewhat reassured if the bankruptcy terms are agreeable to management.
But it's not JUST a short squeeze. I think the pieces of our transformation are in place to completely reinvent who we are, with some type of regulatory approval, and a partnership that will result in billions of revenue dollars.
The precedent would be the previous recall of our loaned shares. Evidence of that preparation would be in the design of our share structure.
Covid changed everything. I wouldn't want to see management dedicate one more day, or one more dollar, exclusively focused on getting lenz approved, "instead of" simultaneously safeguarding shareholders and our intellectual property.
We're about to see one of the biggest revenue payouts in history, claimed by the smallest company ever to succeed.
I might keep looking, but I don't see any enforcement actions filed by the SEC either as an Admin Proceeding, or as a Litigation Release, against Dale.
I found a record filed in the US District Court for the Eastern District of Pennsylvania on August 11, 2023.
https://dockets.justia.com/docket/pennsylvania/paedce/2:2023mc00115/612553
And I found a record of Dale's Appeal filed in the U.S. Court of Appeals, Third Circuit, on October 4, 2023
https://dockets.justia.com/docket/circuit-courts/ca3/23-2776
Several of the docketed items are sealed.
So I can't make a connection between these proceedings and the Humanigen bankruptcy case. But I feel confident that connection exists, and by Dale prevailing in his Appeal, that will bode well for the bankruptcy case, if not obliterate it.
'Stocktwits' poster TwongStocks notes, "Seems the parties have worked out their issues. Per para 5, the US Trustee and UCC do not object to this revision. Taran does not consent or object. So as long as there are no more objections, the Court will likely finalize the bid procedures order."
https://stocktwits.com/TwongStocks/message/559238962
We'll have to see if the issues that were worked out relate to Dale's Appeal, as I suspect to be the case.
Is State Street reflecting shares of Humanigen being transferred to Novavax?
https://fintel.io/so/us/hgen/state-street
https://www.sec.gov/Archives/edgar/data/93751/000009375124000204/Novavax_Inc.txt
Heck if I know.
To be honest with you, I've been 'off' the whole week so far, all because I had to break from my routine for a lab appointment at my doctor's office at 10am Monday. I can only imagine that that was the latest appointment time they had available. My follow-up with my PA is at 3pm this coming Monday, not another god-awful morning excursion, which I just don't do normally. And as it would happen, I woke up at 1am Monday. Didn't eat anything because I seem to fall asleep after eating. So after the lab work, I went to the post office, Dollar General (all in the same block), and hit a McDonald's drive-thru at the next exit, since I was hungry.
By the time I got home from my grueling endeavor, I managed to develop muscle pain in my back. It ruined my appetite. So I tried to sleep it off, to no avail. Finally, I remembered that I have extra-strength Tylenol, which I hardly ever take.
Of course, this is when Humanigen decides to juggle two lawsuits at the same time. And two offers, from the DIP lender, and the tort lawyer.
Dang, I'm lucky to be alive after the terrible ordeal this week has proven to be for me.
Yes, I conceded to your excellent point. Nevertheless, DTG is positioned to enter a sell order with Durrant's offer as a benchmark. I don't think he will do that, but it's got to be nice to be positioned as he is.
"New long COVID study uncovers high inflammation in patients as Senate calls for more research on 'crisis'"
ASHLEY RIEGLE
Wed, January 24, 2024
https://www.yahoo.com/gma/long-covid-study-uncovers-high-011010645.html
If Long Covid has now advanced to the crisis stage, and since it is caused by high inflammation, how much longer can lenz be ignored as the premier treatment therapeutic for this indication? Or, HAS lenz been ignored? I recall that lenz was submitted as a treatment candidate for this indication. Is Long Covid going to be a new indication for lenz, causing regulatory approval and further stimulating investor demand ahead of the company's recall of their loaned shares? Is this why Durrant is both the stalking horse bidder, as well as the DIP lender?
Yes, it may be laughable. But not so much when compared to an average cost basis of $0.00027, for millions of shares. I'm very happy for DTG.
No, you're correct, sosjtb. Thank you for clarifying that. I screwed up a couple of things lately, like buying GB Sciences stock, when I was trying to buy my first ETF. And I did not comply with the procedure for requesting exclusion from the Class Action litigation. They explained some of the reasoning that a shareholder may decide to exclude himself from litigation. But they failed to note that someone like me would be more inclined to join a suit against the tort lawyer. We'll see how that develops.
I don't know who would provide the locates for ~4M shares for $11K. But you could be right. I certainly share your disdain for naked shorters, and I feel proud of the fact that the SEC actually charged Penson Financial for Naked Shorting.
You vacillated, but you ultimately bit the bullet and you have a guaranteed payout of just under $200K. So I hope your exit strategy may not necessarily be binary, and that you don't "go home broke."
Your acquisition certainly sent a signal to the shorts that the bankruptcy has not deterred retail interest in this stock.
But I think the Q suffix was timed to coincide with management's conclusion of the accumulation of shares in preparation for the recall of the company's loaned shares. Note the share volume in the two days preceding the Q designation on the 5th.
https://ih.advfn.com/stock-market/USOTC/humanigen-ce-HGEN/historical/more-historical-data
My guess is that management provided those shares for you, and that's why I think our ownership of the company may have been reduced from 92% to 89%. I think it was a very generous and gracious display of management's consideration of a shareholder. I think they provided just enough shares to keep you from filing Beneficial Ownership documentation.
I mentioned the 89-92% control in a separate post. "I've been wondering if Dale's Appeal hearing might force disclosure regarding the amount of Humanigen stock controlled by the company, which I think could range from 89-92%, which would cause one heck of a short squeeze, if the company recalled their loaned shares, and would mean that the bankruptcy petition could be withdrawn."
The company may not want to withdraw the bankruptcy petition. But I mention it because I doubt that the objections being filed are considering this possibility.
However, I think that our partners are likely aware of the company's strategy. After all, they are incurring most of the trial costs for CAR-T, CMML, and AGvHD.
Of particular note is the lack of recognizing the covid opportunity. Management has not chosen to recognize a partnership for this indication, which I think will result in more revenue, and save more lives, than all of the other indications combined. I've made clear my own opinion that Novavax may prove to be a partner for us by using the lenz vaccine cocktail, and expanding our market upstream of hospitalized covid patients, to include the prophylaxis use of lenz.
Shareholders are on the threshold of life-changing reward, and the whole world is on the threshold of having a life-saving covid vaccine and therapeutic.
I've been wondering if Dale's Appeal hearing might force disclosure regarding the amount of Humanigen stock controlled by the company, which I think could range from 89-92%, which would cause one heck of a short squeeze, if the company recalled their loaned shares, and would mean that the bankruptcy petition could be withdrawn. That's not a new thought, so I may have a degree of bias in continuing to believe that.
Still, I see new evidence in support of that conclusion.
The bankruptcy HEARING HAS BEEN ADJOURNED TO JANUARY 23, 2024
AT 2:00 P.M. (ET) WITH PERMISSION FROM THE COURT.
https://document.epiq11.com/document/getdocumentbycode?docId=4283561&projectCode=HUM&source=DM
Isn't that the same time Dale's Appeal hearing is scheduled?
Another miss for Gilead, in a key market segment for ADC's.
"Trodelvy belongs to a class of widely sought-out treatments called antibody-drug conjugates, or ADCs, which deliver a cancer-killing therapy to specifically target and kill cancer cells and minimize damage to healthy ones. Standard chemotherapy is less selective — it can affect both cancer cells and healthy cells.
ADCs are one of the hottest areas of the pharmaceutical industry, as large drugmakers ink deals to acquire or co-develop them."
https://www.cnbc.com/2024/01/22/gilead-stock-falls-after-disappointing-lung-cancer-study-results.html
Exclusion from Litigation
From: Jay Booth
To: aapton@zlk.com
Sent: Sunday, January 21, 2024 at 10:44:06 AM CST
Subject: Exclusion from Litigation
I do not want to be included in the litigation against Humanigen in: Case No. 2:22-cv-05258-WJM-AME
Jay Booth
That's awesome, DTG! I wonder if we'll see a drop from 92% to 89%. Maybe the Hearing tomorrow will force disclosure on share data.
There's a lot more that went into preparing for this recall of the company's loaned shares, than we saw in the previous recall.
We spent millions on achieving the stellar results lenzilumab demonstrated in LIVE-AIR and in the PREACH-M trials. We have proven that lenz should be the Standard of Care for covid. That compares to previously leading with benznidazole for the treatment of Chagas Disease.
In addition, the PREACH-M interim results show CMML patients trending toward near-normal hematological parameters. This improvement could lead to treated patients undergoing bone marrow transplant, for the complete eradication of CMML cancer, as the RATinG study seems to be showing.
Also, we are forming partnerships that we didn't previously have. These partners are looking to advance their own platforms, CAR-T's, vaccines, and therapeutics, all of which are dramatically enhanced by incorporating lenz in their treatments.
Finally, I think management may have secured as much as 92% of the company's stock, greater than the 70% ownership previously obtained.
I'm trying to learn from this experience. Right now, I'm keen on observing management's strategic positioning of the company in preparation for the recall of their loaned shares. It was the previous recall that alerted me to this company. So I hope that I have learned about all the moving parts necessary to once again get the company positioned to lower the boom on short sellers. It's been a valuable learning experience, even if it incorporates components that I wish weren't necessary. I appreciate the education this has yielded. It's a live demonstration that we may never see again.
I'm trying to add to my position also, Yooo, even if indirectly. I put a small bid in for:
"GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market." I had mentioned this company before, and it looks like 'ShortVolumes.com' finally updated Humanigen's chart in this regard, before the ticker change.
http://shortvolumes.com/?t=HGEN
Since adding the Q suffix, Shortvolumes.com now shows:
http://shortvolumes.com/?t=hgenq
It's not that I'm wild about taking a very small position in an ETF. I'm certainly not. But so far, in trying to contact Taran, I have only gotten as far as registering with Companies House, complete with a dashboard by Endole. I don't have enough money to justify continued effort.
I mention my pathetic effort only to demonstrate my desire to buy as many shares as I can. And at least this post shows the new page link for Humanigen on the ShortVolumes.com website.
I agree that a pathway to success was delayed. But management recognized the obstacles and developed alternative pathways, to ensure that we will succeed.
Delayed filings are a small price to pay, to put a stop to these preventable deaths.
As I've shown before, most of the damage to our company was caused by a lack of regulatory approval, and the PPS decline since becoming delinquent in filing the second quarter 10-Q was comparatively minimal...and temporary.
Nothing you have ever said more clearly demonstrates your total lack of comprehending the circumstances that are resulting in the preventable loss of lives everyday. You're damn right, I blame the FDA.
I hope Dale gets a favorable decision from the Appeals Court on Tuesday, and that I don't have to spend time on what looks like a complicated set of circumstances. We'll know soon enough.
But when you take the design of our share structure, involving ~ 6-8 entities controlled by Dale, and the Admin Proceeding filed against Murchinson, it's easy for the SEC to force Dale to prove his innocence, which is NOT the way the system is designed, except for the IRS.
"1. These proceedings concern Respondents causing the executing brokers of
a hedge fund (the “Hedge Fund”) to violate the order-marking and locate requirements of
Regulation SHO of the Exchange Act, and Respondents Murchinson and Bistricer (the
“Murchinson Respondents”) causing the Hedge Fund to act as a dealer without
registering with the Commission, or being exempt from registration, in violation of
Section 15(a)(1) of the Exchange Act.2
2. From January 2016 through October 2017 (the “relevant period”),
Respondents caused the Hedge Fund to place “long” sale orders with its brokers. At the
time hundreds of these orders were entered, the Hedge Fund was not “deemed to own”
the stock being sold and did not have a net long position in the stock for the purposes of
Regulation SHO. Respondents should have identified these orders as “short” sales.
Because this order-marking information was erroneous, Respondents caused the Hedge
Fund’s executing brokers to mismark such sale orders as “long” in violation of Rule
200(g) of Regulation SHO."
https://www.sec.gov/files/litigation/admin/2021/34-92684.pdf
This was further complicated by the Kalobios name change to Humanigen at this time.
"KaloBios Pharmaceuticals Inc. will change its name to Humanigen Inc., effective Aug 7.
The new name reflects the company's focus on neglected and rare disease, said Cameron Durrant, managing director, chairman and CEO of KaloBios."
https://www.globenewswire.com/news-release/2017/07/27/1063782/0/en/KaloBios-To-Change-Company-Name-To-Humanigen-Inc.html
As far as Humanigen's previous CEO, the SEC (heck, the whole US government), had a problem with him.
"The Securities and Exchange Commission (“Commission”) deems it appropriate and in the
public interest that public administrative proceedings be, and hereby are, instituted pursuant to
Section 203(f) of the Investment Advisers Act of 1940 (“Advisers Act”) against Martin Shkreli
(“Shkreli” or “Respondent”)."
https://www.sec.gov/files/litigation/admin/2017/ia-4753.pdf
Even among senior Humanigen shareholders here, there are a number of them who swear up and down that the Form 4's prove that insiders were selling shares, while I think they were only transferring shares between nominee and beneficial owner accounts.
I'm assuming that the action Dale is Appealing is related to the above charges against Murchison. If that is not the case, I'll continue to look for an Admin Proceeding or Litigation Release naming Black Horse.
My nonchalant attitude is because, if these charges really do stem from the Murchinson case, it will be easy for Dale to prove that any funds disgorged from his entities should be returned.
I think this is an over-zealous prosecution by the SEC against all things Shkreli and Kalobios related, especially as our initial recall of our loaned shares would not have been possible if the SEC was controlling naked shorting of the company's stock. That's a lesson that they still haven't learned.
I really should continue to look for the charges relevant to this case. I'll do it if I have to, but the case may be Appealed before then, and I have a lot of confidence in Dale. Fire at will, Dale!
I have no doubt that you want me to be proven right. That's why I was happy to see that you continued to add to your position. Nothing I see gives me reason to stop being supportive of management.
I even think that if I was wrong about some of the things I said, then Dale would not have filed an Appeal. So I take the Appeal as a sign that I was right, even though I haven't seen either the charges or the Appeal.
Hold your fire. Hearing adjourned until the 23rd.
https://document.epiq11.com/document/getdocumentbycode?docId=4283561&projectCode=HUM&source=DM
Fire at will !
There is no reason to stop being supportive of Humanigen, as they continue to execute their business strategy, even while they integrate a stronger structural base.
I believe VERY STRONGLY in lenzilumab. Speaking just as a shareholder, I think lenz will have a shocking level of commercial success, maybe unparalleled in it's scope. That's very important to me. So I want to develop as much appreciation of this opportunity as I can. I want to have some expectations of what to look for.
If all I did was dwell on the PPS, or the delayed filings, I would be clueless about the potential I have for success with lenz. I'm glad that's not me. I guess I'd rather expect too much, than to settle for too little.
It's really not about me doing what management should be doing. I'm not qualified to do that. But to the extent that I can learn about this drug on my own, I think it's in my own best interest to do so.